Canada
NovoBind is a Canadian biotechnology startup founded in 2012. The company specializes in animal health and utilizes next-generation biologics to target and neutralize key pathogens affecting producers and food safety. NovoBind's focus is on pathogens that cause over $1 billion in production losses, particularly those impacted by antibacterial resistance, regulatory bans on antibiotics, and changing consumer sentiment.
The company recently received a $30.00K grant investment on April 19, 2023. Currently, there is no information available on the specific investors involved in this latest round of funding.
NovoBind operates in the biotechnology and health care industries, positioning itself at the forefront of addressing critical challenges in animal health. With its innovative approach and potential to disrupt traditional methods in the industry, NovoBind presents an intriguing opportunity for venture capital firms seeking investment prospects in the biotech and health care sectors.
